This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

5 Stories You Can't Miss About Big Pharma, Facebook: StockTwits

NEW YORK (TheStreet) -- Each day we see thousands of links shared on StockTwits. The diversity is incredible, with links to articles, blog posts, charts and videos. We combed through the StockTwits stream today and found these five stories that you have to see. 

1. The American public still isn't interested in the stock market, though the S&P 500 (^GSPC) is up roughly 116% since 2009. Take a look at this link:

Great story by @ben_rooney on how 73% of Americans still don't want to invest in stocks $SPX $SPY via @cnnmoneyinvest

-- Ryan Detrick (@RyanDetrick) Apr. 22 at 10:23 AM

2. Goldman Sachs released a note about M&A activity in the biotech and pharmaceutical sectors. It essentially hints that the entire industry is entering a phase of mega deals. They might be right, too. Novartis (NVS - Get Report), GlaxoSmithKline (GSK - Get Report) and Eli Lilly (LLY) recently swapped billions in assets like a game of Uno:

Here's my graphic that summarizes the $NVS $GSK $LLY deal:

-- Brad Loncar (@bradloncar) Apr. 22 at 09:06 AM

Here's the $GSK PR - so $GSK and $NVS are going to create a new consumer healthcare business too. 3-way transaction.

-- Brad Loncar (@bradloncar) Apr. 22 at 01:31 AM

1 of 2

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free
GSK $42.91 -1.04%
NVS $75.97 -1.09%
AAPL $93.74 -1.15%
FB $117.58 0.73%
GOOG $693.01 0.29%


Chart of I:DJI
DOW 17,773.64 -57.12 -0.32%
S&P 500 2,065.30 -10.51 -0.51%
NASDAQ 4,775.3580 -29.9330 -0.62%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs